MBCProject_0582_T1_RNA
— · D
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- D
- subtype
- D
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- INTERFERON_ALPHA_RESPONSE+0.450
- INTERFERON_GAMMA_RESPONSE+0.360
- ALLOGRAFT_REJECTION+0.280
- INFLAMMATORY_RESPONSE+0.260
- WNT_BETA_CATENIN_SIGNALING+0.260
- IL6_JAK_STAT3_SIGNALING+0.250
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.230
- TNFA_SIGNALING_VIA_NFKB+0.220
- MITOTIC_SPINDLE+0.200
- IL2_STAT5_SIGNALING+0.190
Top 10 suppressed
- OXIDATIVE_PHOSPHORYLATION-0.580
- PROTEIN_SECRETION-0.500
- MYC_TARGETS_V1-0.390
- ADIPOGENESIS-0.340
- FATTY_ACID_METABOLISM-0.330
- PEROXISOME-0.300
- MTORC1_SIGNALING-0.260
- ANDROGEN_RESPONSE-0.250
- ESTROGEN_RESPONSE_LATE-0.250
- PANCREAS_BETA_CELLS-0.250
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | TCGA-EW-A3U0-01A-11R-A22K-07 | — | D | 0.867 |
| 2 | 20030032.TNBC | — | D | 0.865 |
| 3 | TCGA-AC-A8OQ-01A-11R-A41B-07 | — | D | 0.836 |
| 4 | MBCProject_0375_T1_A_RNA | — | D | 0.817 |
| 5 | TCGA-MP-A4T4-01A-11R-A262-07 | — | cohortA1 | 0.817 |
| 6 | SRR8518351 | — | D | 0.812 |
| 7 | TCGA-A2-A0SX-01A-12R-A084-07 | — | D | 0.808 |
| 8 | MBCProject_7544_T1_RNA | — | D | 0.808 |
| 9 | BS_PGHK1JRW | ATRT | — | 0.807 |
| 10 | SRR8518330 | — | D | 0.804 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 27 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| INTERFERON_ALPHA_RESPONSE | 0.450 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.360 | Idelalisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.280 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.260 | Idelalisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.260 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.250 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.230 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.220 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.200 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.190 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.180 | Temsirolimus | — uncovered |
| ANGIOGENESIS | 0.170 | Remibrutinib | — uncovered |
| MYC_TARGETS_V2 | 0.160 | Idelalisib | — uncovered |
| MYOGENESIS | 0.130 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.120 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.120 | Inavolisib | — uncovered |
| COAGULATION | 0.110 | Binimetinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.110 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.110 | Remibrutinib | — uncovered |
| HYPOXIA | 0.100 | Idelalisib | — uncovered |